160 related articles for article (PubMed ID: 34322698)
1. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer.
Strati A; Zavridou M; Kallergi G; Politaki E; Kuske A; Gorges TM; Riethdorf S; Joosse SA; Koch C; Bohnen AL; Mueller V; Koutsodontis G; Kontopodis E; Poulakaki N; Psyrri A; Mavroudis D; Georgoulias V; Pantel K; Lianidou ES
Clin Chem; 2021 Oct; 67(10):1395-1405. PubMed ID: 34322698
[TBL] [Abstract][Full Text] [Related]
2. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.
Stergiopoulou D; Markou A; Strati A; Zavridou M; Tzanikou E; Mastoraki S; Kallergi G; Georgoulias V; Lianidou E
Sci Rep; 2023 Jan; 13(1):1258. PubMed ID: 36690653
[TBL] [Abstract][Full Text] [Related]
4.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
5. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
7. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
[TBL] [Abstract][Full Text] [Related]
8. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
[TBL] [Abstract][Full Text] [Related]
9. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
[TBL] [Abstract][Full Text] [Related]
10. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
11. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
13. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
[TBL] [Abstract][Full Text] [Related]
14. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
16. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
[TBL] [Abstract][Full Text] [Related]
17. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
[TBL] [Abstract][Full Text] [Related]
18. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma.
Zavridou M; Mastoraki S; Strati A; Koutsodontis G; Klinakis A; Psyrri A; Lianidou E
Sci Rep; 2020 Apr; 10(1):6551. PubMed ID: 32300118
[TBL] [Abstract][Full Text] [Related]
20. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
